Correlation analyses of PRO endpoints at month 3
| HAQ-DI | SF-36v2† PF | SF-36v2† BP | Pain-VAS | EQ-5D-3L P/D | |
| Tofacitinib 5 mg twice daily (N=124) | |||||
| HAQ-DI | 1 | −0.80 | −0.71 | 0.63 | 0.55 |
| SF-36v2† PF | – | 1 | 0.70 | −0.59 | −0.51 |
| SF-36v2† BP | – | – | 1 | −0.78 | −0.62 |
| Pain-VAS | – | – | – | 1 | 0.61 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
| Tofacitinib 10 mg twice daily (N=119) | |||||
| HAQ-DI | 1 | −0.79 | −0.72 | 0.66 | 0.57 |
| SF-36v2† PF | – | 1 | 0.79 | −0.70 | −0.52 |
| SF-36v2† BP | – | – | 1 | −0.74 | −0.64 |
| Pain-VAS | – | – | – | 1 | 0.61 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
| Placebo (N=117) | |||||
| HAQ-DI | 1 | −0.81 | −0.70 | 0.62 | 0.45 |
| SF-36v2† PF | – | 1 | 0.72 | −0.63 | −0.48 |
| SF-36v2† BP | – | – | 1 | −0.78 | −0.63 |
| Pain-VAS | – | – | – | 1 | 0.61 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
All correlations were ***p<0.001, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the analysis included patients with observations at a visit of interest in Full Analysis Set.
†SF‑36v2 scores are norm-based.
BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions-3-level; HAQ‑DI, Health Assessment Questionnaire Disability Index; N, the number of patients included in calculating the sample correlation; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.